SEARCH

SEARCH BY CITATION

References

  • 1
    Louis DN, Ohgaki H, Wiestler OD, et al. The 2007 WHO classification of tumours of the central nervous system. Acta Neuropathol. 2007; 114: 97-109.
  • 2
    Karim AB, Maat B, Hatlevoll R, et al. A randomized trial on dose-response in radiation therapy of low-grade cerebral glioma: European Organization for Research and Treatment of Cancer (EORTC) Study 22844. Int J Radiat Oncol Biol Phys. 1996; 36: 549-556.
  • 3
    Shaw E, Arusell R, Scheithauer B, et al. Prospective randomized trial of low- versus high-dose radiation therapy in adults with supratentorial low-grade glioma: initial report of a North Central Cancer Treatment Group/Radiation Therapy Oncology Group/Eastern Cooperative Oncology Group study. J Clin Oncol. 2002; 20: 2267-2276.
  • 4
    van den Bent MJ, Afra D, de Witte O, et al. Long-term efficacy of early versus delayed radiotherapy for low-grade astrocytoma and oligodendroglioma in adults: the EORTC 22845 randomised trial. Lancet. 2005; 366: 985-990.
  • 5
    Bauman G, Lote K, Larson D, et al. Pretreatment factors predict overall survival for patients with low-grade glioma: a recursive partitioning analysis. Int J Radiat Oncol Biol Phys. 1999; 45: 923-929.
  • 6
    Berben DMMJ. Follow-up of post-op irradiation for low-grade gliomas: results [abstract]. Neuro Oncol. 2006; 8: 335-336.
  • 7
    Brown PD, Buckner JC, O'Fallon JR, et al. Importance of baseline mini-mental state examination as a prognostic factor for patients with low-grade glioma. Int J Radiat Oncol Biol Phys. 2004; 59: 117-125.
  • 8
    Claus EB, Horlacher A, Hsu L, et al. Survival rates in patients with low-grade glioma after intraoperative magnetic resonance image guidance. Cancer. 2005; 103: 1227-1233.
  • 9
    Daniels TB, Brown PD, Ballman K, et al. Validation of EORTC prognostic factors for adults with low grade glioma: a report utilizing intergroup 86-72-51. Int J Radiat Oncol Biol Phys. 2006; 66( 3 suppl 1): S83.
  • 10
    Janny P, Cure H, Mohr M, et al. Low grade supratentorial astrocytomas: management and prognostic factors. Cancer. 1994; 73: 1937-1945.
  • 11
    Karim ABM, Cornu P, Bleehen N, et al. Immediate postoperative radiotherapy in low grade glioma improves progression free survival but not overall survival: preliminary results of an EORTC/MRC randomized phase III study. Proc Am Soc Clin Oncol. 1998; 17: 400a.
  • 12
    Keles GE, Lamborn KR, Berger MS. Low-grade hemispheric gliomas in adults: a critical review of extent of resection as a factor influencing outcome. J Neurosurg. 2001; 95: 735-745.
  • 13
    Leighton C, Fisher B, Bauman G, et al. Supratentorial low-grade glioma in adults: an analysis of prognostic factors and timing of radiation. J Clin Oncol. 1997; 15: 1294-1301.
  • 14
    Lote K, Egeland T, Hager B, et al. Survival, prognostic factors, and therapeutic efficacy in low-grade glioma: a retrospective study in 379 patients. J Clin Oncol. 1997; 15: 3129-3140.
  • 15
    Marsa GW, Goffinet DR, Rubinstein LJ, Bagshaw MA. Megavoltage irradiation in the treatment of gliomas of the brain and spinal cord. Cancer. 1975; 36: 1681-1689.
  • 16
    Medbery CAIII, Straus KL, Steinberg SM, Cotelingam JD, Fisher WS. Low-grade astrocytomas: treatment results and prognostic variables. Int J Radiat Oncol Biol Phys. 1988; 15: 837-841.
  • 17
    Nicolato A, Gerosa MA, Fina P, Iuzzolino P, Giorgiutti F, Bricolo A. Prognostic factors in low-grade supratentorial astrocytomas: a uni-multivariate statistical analysis in 76 surgically treated adult patients. Surg Neurol. 1995; 44: 208-221.
  • 18
    Pignatti F, van den Bent M, Curran D, et al. Prognostic factors for survival in adult patients with cerebral low-grade glioma. J Clin Oncol. 2002; 20: 2076-2084.
  • 19
    Shafqat S, Hedley-Whyte ET, Henson JW. Age-dependent rate of anaplastic transformation in low-grade astrocytoma. Neurology. 1999; 52: 867-869.
  • 20
    Shaw EG, Daumas-Duport C, Scheithauer BW, et al. Radiation therapy in the management of low-grade supratentorial astrocytomas. J Neurosurg. 1989; 70: 853-861.
  • 21
    Shaw EG, Scheithauer BW, Gilbertson DT, et al. Postoperative radiotherapy of supratentorial low-grade gliomas. Int J Radiat Oncol Biol Phys. 1989; 16: 663-668.
  • 22
    Shaw EG, Scheithauer BW, O'Fallon JR. Supratentorial gliomas: a comparative study by grade and histologic type. J Neurooncol. 1997; 31: 273-278.
  • 23
    Rosenblum MK. The 2007 WHO Classification of Nervous System Tumors: newly recognized members of the mixed glioneuronal group. Brain Pathol. 2007; 17: 308-313.
  • 24
    Smith JS, Chang EF, Lamborn KR, et al. The role of extent of resection in the long-term outcome of low-grade hemispheric gliomas [abstract]. Neuro Oncol. 2007; 9: 599-600.
  • 25
    Westergaard L, Gjerris F, Klinken L. Prognostic parameters in benign astrocytomas. Acta Neurochir (Wien). 1993; 123: 1-7.
  • 26
    Winger MJ, Macdonald DR, Cairncross JG. Supratentorial anaplastic gliomas in adults: the prognostic importance of extent of resection and prior low-grade glioma. J Neurosurg. 1989; 71: 487-493.
  • 27
    Hanzely Z, Polgar C, Fodor J, et al. Role of early radiotherapy in the treatment of supratentorial WHO Grade II astrocytomas: long-term results of 97 patients. J Neurooncol. 2003; 63: 305-312.
  • 28
    Shaw EG, Won M, Brachman DG, et al. Preliminary results of RTOG Protocol 9802: a phase II study of observation in completely resected adult low-grade glioma. Neuro Oncol. 2005; 7: 284.
  • 29
    Chi A, Batchelor TT. Low-grade gliomas in older patients: a malignant tumor? Neuro Oncol. 2007; 9: 545.
  • 30
    Laws ERJr, Taylor WF, Clifton MB, Okazaki H. Neurosurgical management of low-grade astrocytoma of the cerebral hemispheres. J Neurosurg. 1984; 61: 665-673.
  • 31
    Shaw E, Arusell R, Scheithauer B, et al. A prospective randomized trial of low- versus high-dose radiation therapy in adults with supratentorial low-grade glioma: initial report of a NCCTG-RTOG-ECOG study. Proc Am Soc Clin Oncol. 1998; 17: 401a.
  • 32
    van Veelen ML, Avezaat CJ, Kros JM, van Putten W, Vecht C. Supratentorial low grade astrocytoma: prognostic factors, dedifferentiation, and the issue of early versus late surgery. J Neurol Neurosurg Psychiatry. 1998; 64: 581-587.
  • 33
    Pouratian N, Mut M, Jagannathan J, Lopes MB, Shaffrey ME, Schiff D. Low-grade gliomas in older patients: a retrospective analysis of prognostic factors. J Neurooncol. 2008; 90: 341-350.
  • 34
    Karim AB, Afra D, Cornu P, et al. Randomized trial on the efficacy of radiotherapy for cerebral low-grade glioma in the adult: European Organization for Research and Treatment of Cancer Study 22845 with the Medical Research Council study BRO4: an interim analysis. Int J Radiat Oncol Biol Phys. 2002; 52: 316-324.
  • 35
    Kernohan JW, Sayre GP. Tumors of the Central Nervous System. Washington, DC: Armed Forces Institute of Pathology; 1952: 17-42.
  • 36
    Zulch KJ. World Health Organization Classification of Tumours. Histological Typing of Tumours of the Central Nervous System. Geneva, Switzerland: World Health Organization; 1979.
  • 37
    Kaplan EL, Meier P. Non-parametric estimation from incomplete observations. J Am Stat Assoc. 1958; 53: 457-481.
  • 38
    Peto R, Pike MC, Armitage P, et al. Design and analysis of randomized clinical trials requiring prolonged observation of each patient. II. Analysis and examples. Br J Cancer. 1977; 35: 1-39.
  • 39
    Schomas DA, Laack NN, Rao RD, et al. Intracranial low-grade gliomas in adults: 30-year experience with long-term follow-up at Mayo Clinic. Neuro Oncol. 2008 Nov 18 [Epub ahead of print].
  • 40
    Cox DR. Statistical significance tests. Br J Clin Pharmacol. 1982; 14: 325-331.
  • 41
    Simpson JR, Horton J, Scott C, et al. Influence of location and extent of surgical resection on survival of patients with glioblastoma multiforme: results of 3 consecutive Radiation Therapy Oncology Group (RTOG) clinical trials. Int J Radiat Oncol Biol Phys. 1993; 26: 239-244.
  • 42
    Walker MD, Strike TA, Sheline GE. An analysis of dose-effect relationship in the radiotherapy of malignant gliomas. Int J Radiat Oncol Biol Phys. 1979; 5: 1725-1731.
  • 43
    Walker MD, Alexander EJr, Hunt WE, et al. Evaluation of BCNU and/or radiotherapy in the treatment of anaplastic gliomas: a cooperative clinical trial. J Neurosurg. 1978; 49: 333-343.
  • 44
    Lacroix M, Abi-Said D, Fourney DR, et al. A multivariate analysis of 416 patients with glioblastoma multiforme: prognosis, extent of resection, and survival. J Neurosurg. 2001; 95: 190-198.
  • 45
    Curran WJJr, Scott CB, Horton J, et al. Recursive partitioning analysis of prognostic factors in 3 Radiation Therapy Oncology Group malignant glioma trials. J Natl Cancer Inst. 1993; 85: 704-710.
  • 46
    Kristiansen K, Hagen S, Kollevold T, et al. Combined modality therapy of operated astrocytomas grade III and IV: confirmation of the value of postoperative irradiation and lack of potentiation of bleomycin on survival time: a prospective multicenter trial of the Scandinavian Glioblastoma Study Group. Cancer. 1981; 47: 649-652.
  • 47
    Athanassiou H, Synodinou M, Maragoudakis E, et al. Randomized phase II study of temozolomide and radiotherapy compared with radiotherapy alone in newly diagnosed glioblastoma multiforme. J Clin Oncol. 2005; 23: 2372-2377.
  • 48
    Laramore GE, Martz KL, Nelson JS, Griffin TW, Chang CH, Horton J. Radiation Therapy Oncology Group (RTOG) survival data on anaplastic astrocytomas of the brain: does a more aggressive form of treatment adversely impact survival? Int J Radiat Oncol Biol Phys. 1989; 17: 1351-1356.
  • 49
    Levin VA, Silver P, Hannigan J, et al. Superiority of post-radiotherapy adjuvant chemotherapy with CCNU, procarbazine, and vincristine (PCV) over BCNU for anaplastic gliomas: NCOG 6G61 final report. Int J Radiat Oncol Biol Phys. 1990; 18: 321-324.
  • 50
    Prados MD, Scott C, Curran WJJr, Nelson DF, Leibel S, Kramer S. Procarbazine, lomustine, and vincristine (PCV) chemotherapy for anaplastic astrocytoma: a retrospective review of radiation therapy oncology group protocols comparing survival with carmustine or PCV adjuvant chemotherapy. J Clin Oncol. 1999; 17: 3389-3395.
  • 51
    Cairncross G, Berkey B, Shaw E, et al. Phase III trial of chemotherapy plus radiotherapy compared with radiotherapy alone for pure and mixed anaplastic oligodendroglioma: Intergroup Radiation Therapy Oncology Group Trial 9402. J Clin Oncol. 2006; 24: 2707-2714.
  • 52
    van den Bent MJ, Carpentier AF, Brandes AA, et al. Adjuvant procarbazine, lomustine, and vincristine improves progression-free survival but not overall survival in newly diagnosed anaplastic oligodendrogliomas and oligoastrocytomas: a randomized European Organisation for Research and Treatment of Cancer phase III trial. J Clin Oncol. 2006; 24: 2715-2722.
  • 53
    Ino Y, Betensky RA, Zlatescu MC, et al. Molecular subtypes of anaplastic oligodendroglioma: implications for patient management at diagnosis. Clin Cancer Res. 2001; 7: 839-845.
  • 54
    Ino Y, Zlatescu MC, Sasaki H, et al. Long survival and therapeutic responses in patients with histologically disparate high-grade gliomas demonstrating chromosome 1p loss. J Neurosurg. 2000; 92: 983-990.
  • 55
    Smith JS, Chang EF, Lamborn KR, et al. Role of extent of resection in the long-term outcome of low-grade hemispheric gliomas. J Clin Oncol. 2008; 26: 1338-1345.
  • 56
    Mulhern RK, Ochs J, Kun LE. Changes in intellect associated with cranial radiation therapy. In: Gutin PH, Leibel SA, Sheline GE, eds. Radiation Injury to the Nervous System. New York, NY: Raven Press; 1991: 325-340.
  • 57
    McGirt MJ, Chaichana KL, Attenello FJ, et al. Extent of surgical resection is independently associated with survival in patients with hemispheric infiltrating low-grade gliomas. Neurosurgery. 2008; 63: 700-707.
  • 58
    Shaw EG, Berkey B, Coons SW, et al. Initial report of Radiation Therapy Oncology Group (RTOC) 9802: prospective studies in adult low-grade glioma (LGG) [abstract]. J Clin Oncol. 2006; 24( 18 suppl): 1500.
  • 59
    Schultheiss TE, Kun LE, Ang KK, Stephens LC. Radiation response of the central nervous system. Int J Radiat Oncol Biol Phys. 1995; 31: 1093-1112.
  • 60
    Bahary JP, Villemure JG, Choi S, et al. Low-grade pure and mixed cerebral astrocytomas treated in the CT scan era. J Neurooncol. 1996; 27: 173-177.
  • 61
    Cairncross JG, Laperriere NJ. Low-grade glioma. To treat or not to treat? Arch Neurol. 1989; 46: 1238-1239.
  • 62
    Grabenbauer GG, Roedel CM, Paulus W, et al. Supratentorial low-grade glioma: results and prognostic factors following postoperative radiotherapy. Strahlenther Onkol. 2000; 176: 259-264.
  • 63
    Jubelirer SJ, Rubin M, Shim C. An analysis of 38 cases of low-grade cerebral astrocytoma in adults. W V Med J. 1993; 89: 102-105.
  • 64
    Morantz RA. Radiation therapy in the treatment of cerebral astrocytoma. Neurosurgery. 1987; 20: 975-982.
  • 65
    Olson JD, Riedel E, DeAngelis LM. Long-term outcome of low-grade oligodendroglioma and mixed glioma. Neurology. 2000; 54: 1442-1448.
  • 66
    Philippon JH, Clemenceau SH, Fauchon FH, Foncin JF. Supratentorial low-grade astrocytomas in adults. Neurosurgery. 1993; 32: 554-559.
  • 67
    Piepmeier J, Christopher S, Spencer D, et al. Variations in the natural history and survival of patients with supratentorial low-grade astrocytomas. Neurosurgery. 1996; 38: 872-878.
  • 68
    Recht LD, Lew R, Smith TW. Suspected low-grade glioma: is deferring treatment safe? Ann Neurol. 1992; 31: 431-436.
  • 69
    Reijneveld JC, Sitskoorn MM, Klein M, Nuyen J, Taphoorn MJ. Cognitive status and quality of life in patients with suspected versus proven low-grade gliomas. Neurology. 2001; 56: 618-623.
  • 70
    Soffietti R, Chio A, Giordana MT, Vasario E, Schiffer D. Prognostic factors in well differentiated cerebral astrocytomas in the adult. Neurosurgery. 1989; 24: 686-692.
  • 71
    Eyre HJ, Crowley JJ, Townsend JJ, et al. A randomized trial of radiotherapy versus radiotherapy plus CCNU for incompletely resected low-grade gliomas: a Southwest Oncology Group study. J Neurosurg. 1993; 78: 909-914.
  • 72
    Hoang-Xuan K, Capelle L, Kujas M, et al. Temozolomide as initial treatment for adults with low-grade oligodendrogliomas or oligoastrocytomas and correlation with chromosome 1p deletions. J Clin Oncol. 2004; 22: 3133-3138.
  • 73
    Kaloshi G, Benouaich-Amiel A, Diakite F, et al. Temozolomide for low-grade gliomas: predictive impact of 1p/19q loss on response and outcome. Neurology. 2007; 68: 1831-1836.